Telix Pharma Submits BLA For TLX250-CDx Kidney Cancer Imaging To FDA
Telix Pharmaceuticals Limited (TLX) said that it has submitted its Biologics License Application (BLA) to the U.S. Food and Drug ...
TMCnet2d
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
TLX250-CDx is an investigational PET 3 drug product for the non-invasive diagnosis and characterization of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer ...
Telix Seeks FDA Approval for Kidney Cancer Imaging
Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall ...